Celldex Therapeutics, Inc., a biopharmaceutical company, is striving to develop therapeutic monoclonal and bispecific antibodies for numerous diseases, including inflammatory diseases and various forms of cancer. The clinical development programs of the company comprise of CDX-0159, which is a Phase II monoclonal antibody binding the receptor tyrosine kinase KIT and inhibiting its activity; CDX-1140, a human agonist monoclonal antibody, specifically targeted at CD40, a critical activator of the immune response; and CDX-527, a bispecific antibody using the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway. This aims to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics has several research collaboration and license agreements, such as with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company, incorporated in 1983, is presently headquartered in Hampton, New Jersey.